Homology Medicines, Inc. (0T6G.L)
USD 3.22
(-5.26%)
USD 3.22
(-5.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 118.53 Million USD | 134.76% |
| 2022 | 50.49 Million USD | 20.02% |
| 2021 | 42.07 Million USD | -37.9% |
| 2020 | 67.74 Million USD | 30.12% |
| 2019 | 52.06 Million USD | -17.02% |
| 2018 | 62.73 Million USD | 59.96% |
| 2017 | 39.22 Million USD | 483.75% |
| 2016 | 6.71 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 90.69 Million USD | -12.43% |
| 2024 Q1 | 103.56 Million USD | -55.58% |
| 2023 Q1 | 45.98 Million USD | -8.93% |
| 2023 Q3 | 51.85 Million USD | 3.78% |
| 2023 FY | 233.12 Million USD | 361.71% |
| 2023 Q4 | 233.12 Million USD | 349.6% |
| 2023 Q2 | 49.96 Million USD | 8.66% |
| 2022 Q3 | 53.59 Million USD | 20.91% |
| 2022 Q2 | 44.32 Million USD | -0.86% |
| 2022 Q1 | 44.7 Million USD | 6.26% |
| 2022 Q4 | 50.49 Million USD | -5.78% |
| 2022 FY | 50.49 Million USD | 20.02% |
| 2021 Q3 | 32.24 Million USD | -6.1% |
| 2021 Q4 | 42.07 Million USD | 30.47% |
| 2021 FY | 42.07 Million USD | -37.9% |
| 2021 Q2 | 34.34 Million USD | 1.4% |
| 2021 Q1 | 33.86 Million USD | -50.0% |
| 2020 FY | 67.74 Million USD | 30.12% |
| 2020 Q3 | 58.14 Million USD | -8.49% |
| 2020 Q4 | 67.74 Million USD | 16.52% |
| 2020 Q2 | 63.53 Million USD | 2.07% |
| 2020 Q1 | 62.24 Million USD | 403.05% |
| 2019 Q2 | 15.49 Million USD | -12.22% |
| 2019 FY | 52.06 Million USD | -17.02% |
| 2019 Q1 | 17.64 Million USD | -21.64% |
| 2019 Q4 | 12.37 Million USD | -79.0% |
| 2019 Q3 | 58.93 Million USD | 280.46% |
| 2018 Q2 | 43.51 Million USD | 6.55% |
| 2018 FY | 62.73 Million USD | 59.96% |
| 2018 Q4 | 22.51 Million USD | 21.24% |
| 2018 Q3 | 18.57 Million USD | -57.32% |
| 2018 Q1 | 40.84 Million USD | 360.85% |
| 2017 FY | 39.22 Million USD | 483.75% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q4 | 8.86 Million USD | 0.0% |
| 2016 FY | 6.71 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | 21.007% |
| Dynavax Technologies Corporation | 375.02 Million USD | 68.393% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 75.684% |
| Perrigo Company plc | 6.04 Billion USD | 98.038% |
| Illumina, Inc. | 4.36 Billion USD | 97.285% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 99.772% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | 39.443% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 99.828% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 99.424% |
| Heron Therapeutics, Inc. | 256.47 Million USD | 53.785% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 98.332% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -217.851% |
| Waters Corporation | 3.47 Billion USD | 96.59% |
| Biogen Inc. | 12.04 Billion USD | 99.016% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -43.793% |
| Evolus, Inc. | 209.68 Million USD | 43.471% |
| Adicet Bio, Inc. | 37.12 Million USD | -219.324% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -72.389% |
| bluebird bio, Inc. | 424.62 Million USD | 72.085% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 82.062% |
| FibroGen, Inc. | 585.72 Million USD | 79.763% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 97.59% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -236.961% |
| Geron Corporation | 146.12 Million USD | 18.884% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 97.074% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | 80.811% |
| Myriad Genetics, Inc. | 312.9 Million USD | 62.118% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -490.568% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | 52.74% |
| Zoetis Inc. | 9.29 Billion USD | 98.725% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -141.038% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 96.619% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 93.729% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 97.698% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -144.675% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 95.447% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | 55.226% |
| Verastem, Inc. | 71.18 Million USD | -66.514% |
| Nektar Therapeutics | 267.04 Million USD | 55.613% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | 70.162% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -194.668% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 95.072% |
| OPKO Health, Inc. | 622.47 Million USD | 80.958% |
| Exelixis, Inc. | 678.44 Million USD | 82.529% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 88.372% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -3.241% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -845.692% |
| uniQure N.V. | 624.01 Million USD | 81.005% |
| Imunon, Inc. | 8.53 Million USD | -1289.532% |
| Blueprint Medicines Corporation | 918.64 Million USD | 87.097% |
| Insmed Incorporated | 1.66 Billion USD | 92.867% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 92.814% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | 6.0% |
| TG Therapeutics, Inc. | 169.08 Million USD | 29.897% |
| Incyte Corporation | 1.59 Billion USD | 92.556% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | 90.002% |